Showing 3071-3080 of 4104 results for "".
- LEO Science & Tech Hub and Epicore Biosystems Advance AD Collabhttps://practicaldermatology.com/news/leo-science-tech-hub-and-epicore-biosystems-advance-ad-collab/2460208/LEO Science & Tech Hub, the Boston-based R&D innovation unit of LEO Pharma A/S, is starting the next phase of a research collaboration in atopic dermatitis (AD) with Epicore Biosystems, a wearable microfluidics and biosensor spinout from Northwestern University’s Center for Bio-Inte
- Pinnacle Dermatology Acquires SkinSpeaks Dermatology Clinics in Twin Citieshttps://practicaldermatology.com/news/pinnacle-dermatology-acquires-skinspeaks-dermatology-clinics-in-twin-cities/2460205/Pinnacle Dermatology has acquired SkinSpeaks in the Twin Cities area including locations in Edina, Woodbury, Burnsville, Blaine and Crystal. “We welcome the patients and staff of SkinSpeaks to the Pinnacle Dermatology network of prac
- ASDSA Honors 2019 Patient Safety Heroeshttps://practicaldermatology.com/news/asdsa-honors-2019-patient-safety-heroes/2460203/The American Society for Dermatologic Surgery Association (ASDSA) honored the recipients of its annual Patient Safety Hero awards at the recent ASDS Annual Meeting in Chicago, Illinois. The ASDSA State Legislative Patient Safety Hero Award is presented to a state legislative member who
- Good Oral Health and Diet May Improve Psoriasishttps://practicaldermatology.com/news/good-oral-health-and-diet-may-improve-psoriasis/2460201/Dental health and diet may have an impact on the development and severity of psoriasis, according to researchers from The Ohio State University Wexner Medical Center in Columbus. The study found psoriasis patients who rated their gum health a
- Going for the Gold: Sebacia Microparticles Help Direct Lasers to the Source of Acnehttps://practicaldermatology.com/news/going-for-the-gold-sebacia-microparticles-help-direct-lasers-to-the-source-of-acne/2460199/Sebacia microparticles may be acne’s latest and greatest nemesis. New research presented the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting in Chicago shows that the technology helps to safely and effectively clear acne wh
- Galderma Will Begin Seven New Clinical Studieshttps://practicaldermatology.com/news/galderma-will-begin-seven-new-clinical-studies/2460197/Galderma is initiating seven clinical studies that seek to support potential, new aesthetic indications including a tear trough indication for Restylane, a facial wrinkles indication for Sculptra Aesthetic as well as several studies supporting an investigational liquid neurotoxin and a Phase 2 st
- Arcutis Biotherapeutics Plans to Initiate Phase 3 Program for ARQ-151 for Plaque Psoriasishttps://practicaldermatology.com/news/arcutis-biotherapeutics-plans-to-initiate-phase-3-program-for-arq-151-for-plaque-psoriasis/2460196/Arcutis Biotherapeutics, Inc. plans to initiate its Phase 3 program of ARQ-151 as a potential topical treatment for plaque psoriasis following its End-of-Phase 2 meeting with the FDA. The Company anticipates initiating a Phase 3 clinical trial in the first half of 2020. Frank Watanabe,
- UCB Presents New Data for Cimzia, Investigational Bimekizumabhttps://practicaldermatology.com/news/ucb-presents-new-data-for-cimzia-investigational-bimekizumab/2460193/Data on the use of UCB’s Cimzia (certolizumab pegol), in psoriasis and psoriatic arthritis (PsA) as well as Phase 2 data for the company’s investigational molecule bimekizumab have been presented at the 28thEuropean Academy of Dermatology and Venereology congress (EADV) in Madrid. Cim
- Consumers Cite Dermatologists as Top Influencers of Cosmetic Procedure, Skin Care Choices: ASDShttps://practicaldermatology.com/news/consumers-site-dermatologists-as-top-influencers-of-cosmetic-procedure-skin-care-choices-asds/2460191/When it comes to consumer decisions on cosmetic procedures and skin care choices, dermatologists are the leading influencers, results of the 2019
- Dermira Shares Positive Data From Phase 2b Study of Lebrikizumab for Atopic Dermatitis at Fall Clinical Dermatology Conferencehttps://practicaldermatology.com/news/dermira-shares-positive-data-from-phase-2b-study-of-lebrikizumab-for-atopic-dermatitis-at-fall-clinical-dermatology-conference/2460190/Primary results from Dermira, Inc.'s Phase 2b dose-ranging study of lebrikizumab were presented during the 39th Annual Fall Clinical Dermatology Conference in Las Vegas, NV. Lebrikizumab is currently being evaluated in a Phase 3 program in adult and adolescent patients with moderat